Drug Approval | March 31, 2026
Teva hits major biosimilar milestones with FDA nod and regulatory filings
The US FDA has approved PONLIMSI (denosumab-adet) as a biosimilar to Prolia
The US FDA has approved PONLIMSI (denosumab-adet) as a biosimilar to Prolia
Subscribe To Our Newsletter & Stay Updated